Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 8Gastrointestinal 3Lymphoid 1Dermatologic 1

Conditions

Uveal Melanoma 1Melanoma 1Hyperthermia 1Eye Neoplasms 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Laparotomy × Dermatologic × Clear all
NCT00062933 2012-08-20

A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
40 enrolled
Dermatologic

Hyperthermia, Uveal Melanoma, Eye Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡